NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Bright Minds Biosciences Inc. (DRUG) Stock Analysis

Bright Minds Biosciences Inc. (DRUG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

DRUG

$65.16

−$2.86 (−4.20%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DRUG with… →

DRUG Key Statistics

As of Sep 4, 2026
Trading
Open
$67.84
Previous Close
$68.02
Day's Range
64.53–69.07
52-Week Range
39.70–123.75
Volume
93.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.11
Valuation
Market Cap
$639.35M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.05
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$12.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.81M
1-Year Return
+48.26%
Dividend and dates
Avg Volume
248.03K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DRUG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−16.50%
2025+116.66%
2024+2418.88%
2023−61.35%
2022−76.66%
2021 (partial year)−41.30%

As of September 4, 2026.

DRUG Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$12.23M—
2024$0.00−$2.80M—
2023$0.00−$7.37M—
2022$0.00−$14.96M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$13.94M−$12.23M—
2024$0.00—−$2.82M−$2.80M—
2023$0.00—−$7.39M−$7.37M—
2022$0.00—−$14.98M−$14.96M—

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

DRUG Valuation vs Biotechnology Median

Median of 656 stocks
MetricDRUGBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bright Minds Biosciences Inc. (DRUG) carries a market capitalisation of $639.35M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 26.

Over the past 52 weeks the price has ranged from $39.70 to $123.75. DRUG last closed at $65.16 on September 4, 2026. That is −$2.86 (−4.20%) against the previous close. The latest close sits 64.14% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $12.23M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −2.05.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at −0.11. Daily returns over the trailing 5 years annualize to a volatility of 663.31%. The trailing one-year price return is +48.26%. Across 5 years the annualized return works out at +18.62%.

Growth & Income

No dividend is on file for DRUG.

2026 is still running; the price is −16.50% year to date. Across the complete calendar years on file, 2024 returned +2,418.88% and 2022 returned −76.66%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Bright Minds Biosciences Inc. (DRUG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bright Minds Biosciences Inc. DRUG $639.35M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Bright Minds Biosciences Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Visit website →